Endpoint news has an article noting that FDA just released 5 new guidance documents.
Two are of major interest. The first is a 23 page draft guidance on how FDA will frame its approach to risk/benefit assessments for drugs and biologicals. Here. The second is a 39 page draft guidance on how FDA will assess real world evidence, particularly, EHR data and payor medical claims data. Here.
Risk-benefit frameworks, of course, are also relevant to FDA approval of medical devices and diagnostics, and have analogies to medical benefit (risk/benefit) decisions at payors.
The risk benefit can be summed up in a short table (in an almost comically simple and short table...), although the point of the 23-page document is providing background to what this table really means.